TW202309282A - 抗病毒核酸 - Google Patents

抗病毒核酸 Download PDF

Info

Publication number
TW202309282A
TW202309282A TW111116238A TW111116238A TW202309282A TW 202309282 A TW202309282 A TW 202309282A TW 111116238 A TW111116238 A TW 111116238A TW 111116238 A TW111116238 A TW 111116238A TW 202309282 A TW202309282 A TW 202309282A
Authority
TW
Taiwan
Prior art keywords
bit
nucleic acid
region
cov
sequence
Prior art date
Application number
TW111116238A
Other languages
English (en)
Chinese (zh)
Inventor
中川慎一郎
多賀谷光洋
樋本拓也
神谷亘
Original Assignee
日商日本新藥股份有限公司
國立大學法人群馬大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本新藥股份有限公司, 國立大學法人群馬大學 filed Critical 日商日本新藥股份有限公司
Publication of TW202309282A publication Critical patent/TW202309282A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111116238A 2021-04-28 2022-04-28 抗病毒核酸 TW202309282A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-076521 2021-04-28
JP2021076521 2021-04-28

Publications (1)

Publication Number Publication Date
TW202309282A true TW202309282A (zh) 2023-03-01

Family

ID=83848558

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116238A TW202309282A (zh) 2021-04-28 2022-04-28 抗病毒核酸

Country Status (6)

Country Link
US (1) US20240229035A1 (https=)
EP (1) EP4332223A4 (https=)
JP (1) JPWO2022230974A1 (https=)
CN (1) CN117203339A (https=)
TW (1) TW202309282A (https=)
WO (1) WO2022230974A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023171804A1 (ja) * 2022-03-10 2023-09-14 日本新薬株式会社 抗ウイルスアンチセンスオリゴマー

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
CN111321142A (zh) * 2020-02-05 2020-06-23 翁炳焕 一种新型冠状病毒肺炎dsRNA疫苗的制备方法
CN111330003A (zh) * 2020-03-23 2020-06-26 翁炳焕 一种新冠肺炎反义rna多价疫苗的制备方法
WO2021195025A1 (en) * 2020-03-25 2021-09-30 City Of Hope Antisense rna for treatment of sars-associated coronavirus
CN111778253B (zh) 2020-04-03 2022-02-18 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111748557B (zh) 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
WO2021224918A1 (en) * 2020-05-07 2021-11-11 Eleven Therapeutics Ltd. Utilizing rna interference against sars-cov-2
JPWO2021241040A1 (https=) * 2020-05-27 2021-12-02
CN112111489A (zh) * 2020-06-23 2020-12-22 深圳罗兹曼国际转化医学研究院 抑制SARS-COV-2病毒复制的shRNA及其应用
KR102272800B1 (ko) * 2020-06-30 2021-07-05 국방과학연구소 코로나바이러스 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스 감염증-19 예방 및 치료용 조성물

Also Published As

Publication number Publication date
EP4332223A1 (en) 2024-03-06
US20240229035A1 (en) 2024-07-11
WO2022230974A1 (ja) 2022-11-03
EP4332223A4 (en) 2025-12-31
CN117203339A (zh) 2023-12-08
JPWO2022230974A1 (https=) 2022-11-03

Similar Documents

Publication Publication Date Title
US11851658B2 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
CN109414448B (zh) 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
AU2025279635A1 (en) CRISPR/CAS-related methods and compositions for treating herpes simplex virus
US10612023B2 (en) Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA
TWI816066B (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
CN103391777A (zh) 作为病毒产生调节剂的去乙酰化酶调节剂
US9850486B2 (en) Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
CN112534055A (zh) 用于调节rtel1表达的寡核苷酸
TW202309282A (zh) 抗病毒核酸
KR102700202B1 (ko) 코로나바이러스감염증-19의 치료에 사용하기 위한 SARS-CoV-2 번역 조절 저해 활성을 갖는 안티센스 올리고뉴클레오티드
EP4424827A1 (en) Antiviral antisense oligonucleotide
JP2023161422A (ja) 二本鎖領域を有する抗ウイルス核酸
TW202346589A (zh) 抗病毒反義寡聚物
HK40078459A (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
HK40004694A (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection